Eclipsebio | RNA Solutions

The trusted partner for RNA success

Eclipsebio provides cutting-edge support for making the RNA medicines of tomorrow a success today. From multimodal profiling of critical quality attributes to comprehensive analytics, we provide the solutions needed to move to the clinic with confidence.

eMERGE
RNA Success

eMERGE is the solution for mRNA, saRNA, and circRNA development challenges. Through the integration of our complete technology portfolio, we offer actionable insights into potency, stability, and safety.

Other RNA solutions:

Beyond advancing RNA-based medicine development through eMERGE, we also offer integrative solutions for RNA-targeting therapeutics and RNA research.

AI Training Data

To support accurate AI model training for drug discovery, we provide reproducible datasets through our eVERSE platform. Prepackaged datasets are available for download and custom data can be generated from each of our assays.

Small Oligonucleotides

With our holistic approach to small oligonucleotide design and validation, we provide RNAi and ASO developers with the data needed for clinical success. Learn how we perform multiomic profiling of targets and robustly measure off-target effects.

Target Discovery and Validation

Our integrative portfolio of assays reveals disease-specific, accessible regions of target RNAs and provides deep profiling of on-target and off-target therapeutic effects. Our highly reproducible assays can also be used train AI models for the design of the next generation of small molecule drugs.

Basic Research

Obtain new insights for discoveries into the biology of RNAs with multiomic approaches. For our academic partners we provide a la carte and integrative solutions that deliver a comprehensive overview of RNA biology from secondary structure to protein regulation.

What Our Partners

and Collaborators Say

"Eclipsebio’s analysis of RNA folding has provided valuable insights necessary to understand the impact of RNA sequence and chemical modifications on secondary structures… to help improve the design of our RNAs and rationalize our internal findings."

"Eclipsebio was the only company that could perform the robust siRNA off-target binding analysis we needed. Their experimental results provided important additional insights into our own internal findings. We look forward to continuing to work with Eclipsebio in the future."

"Eclipsebio has been an invaluable partner to Deep Genomics. They've helped us generate massive miRNA-related datasets for training AI models, and have designed and conducted bespoke assays to illuminate the mechanism underlying some of our lead therapeutic compounds."

"At Acuitas we are interested in how modifications to LNP formulations can impact efficacy and stability. Eclipsebio’s eSHAPE assay has potentially revealed direct correlations between LNP composition and RNA secondary structure, further adding to our understanding of the mechanism of action for RNA-LNP systems."

New at Eclipsebio

Discover our latest platform

The effective development of an RNA-based medicine requires comprehensive characterization and precision optimization. With our eMERGE platform, therapeutic developers obtain access to our full portfolio of assays and bioinformatics workflows for drug development success.

Explore our newest technology

A major challenge with RNA vaccines and therapies is the generation of double-stranded RNA (dsRNA) by-products. With our eSENSE dsRNA assay you can measure the level of dsRNA contaminants and determine the sequences and structures that drive dsRNA generation.

Learn with our newest blog

Small interfering RNAs (siRNAs) hold promise for silencing disease-causing genes but face challenges due to off-target effects caused by unintended partial binding to non-target mRNAs. This eBlog discusses the mechanisms of these off-target interactions and outlines strategies to minimize them.

Find out where we will be next

Our team of RNA experts is presenting at conferences and webinars to highlight the power of RNA solutions for therapeutic success. Discover where we will be discussing our platform and partnership opportunities.